Get the Stockscreener App
96.76
0.48%
0.46
After Hours:
96.76
Nuvalent Inc stock is traded at $96.76, with a volume of 174.52K.
It is up +0.48% in the last 24 hours and up +6.68% over the past month.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$96.30
Open:
$96.6
24h Volume:
174.52K
Relative Volume:
0.34
Market Cap:
$6.78B
Revenue:
-
Net Income/Loss:
$-173.59M
P/E Ratio:
-52.30
EPS:
-1.85
Net Cash Flow:
$-130.44M
1W Performance:
+6.13%
1M Performance:
+6.68%
6M Performance:
+42.40%
1Y Performance:
+51.14%
1-Day Range:
$95.03
$97.48
1-Week Range:
$90.11
$97.65
52-Week Range:
$61.02
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
96.76 | 6.78B | 0 | -173.59M | -130.44M | -1.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent director Shair sells shares worth $192,442 - Investing.com
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference - Longview News-Journal
Nuvalent's SWOT analysis: biotech stock shows promise amid clinical trials - Investing.com
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 - GuruFocus.com
Trend Tracker for (NUVL) - Stock Traders Daily
Eagle Asset Management Inc. Reduces Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent Highlights Corporate and Pipeline Achievements, Reitera - GuruFocus.com
Nuvalent CEO Porter sells shares worth $2.37 million By Investing.com - Investing.com Australia
Nuvalent CEO Porter sells shares worth $2.37 million - Investing.com India
Victory Capital Management Inc. Has $15.37 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
First Turn Management LLC Has $36.74 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely - Simply Wall St
FY2024 EPS Estimates for Nuvalent Reduced by Leerink Partnrs - MarketBeat
What is Wedbush's Forecast for Nuvalent FY2024 Earnings? - MarketBeat
Perceptive Advisors LLC Expands Stake in Nuvalent Inc - GuruFocus.com
Paradigm Biocapital Advisors LP Acquires Significant Stake in Nu - GuruFocus.com
State of New Jersey Common Pension Fund D Makes New $2.41 Million Investment in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
How to Take Advantage of moves in (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Announces Quarterly Earnings Results - MarketBeat
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Nuvalent Reports Q3 2024 Progress and Financials - TipRanks
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results - The Malaysian Reserve
Crescent Biopharma Appoints Susan Moran, MD, MSCE, and Alexandra Balcom, MBA, CPA, to Board of Directors - The Malaysian Reserve
Nuvalent Appoints Chief Scientific Officer - Contract Pharma
AlphaCentric Advisors LLC Invests $716,000 in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent CFO Alexandra Balcom sells $891,879 in stock By Investing.com - Investing.com Canada
Nuvalent CFO Alexandra Balcom sells $891,879 in stock - Investing.com
Nuvalent's chief development officer Noci Darlene sells $442,980 in shares - Investing.com
Nuvalent's chief development officer Noci Darlene sells $442,980 in shares By Investing.com - Investing.com Australia
Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom Sells 10,000 Shares - MarketBeat
abrdn plc Sells 40,233 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
(NUVL) Technical Data - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Z - GuruFocus.com
Oversold Conditions For Nuvalent (NUVL) - Nasdaq
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Sci - GuruFocus.com
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com
UBS Initiates Coverage of Nuvalent (NUVL) with Neutral Recommendation - MSN
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $195,500,000.00 in Stock - MarketBeat
Nuvalent sees $195.5 million stock sale by Deerfield Management - Investing.com
Nuvalent (NASDAQ:NUVL) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Where are the Opportunities in (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Shares Gap DownShould You Sell? - MarketBeat
Nuvalent CEO Porter sells shares worth $2.76 million - Investing.com
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) CEO Sells 27,000 Shares of Stock - MarketBeat
Nuvalent CEO Porter sells shares worth $2.76 million By Investing.com - Investing.com UK
AQR Capital Management LLC Has $1.01 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
AQR Capital Management LLC Sells 8,783 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Nov 15 '24 |
Option Exercise |
27.85 |
27,000 |
751,950 |
215,113 |
| Porter James Richard | President and CEO |
Nov 15 '24 |
Sale |
87.94 |
27,000 |
2,374,479 |
188,113 |
| Noci Darlene | Chief Development Officer |
Nov 01 '24 |
Option Exercise |
14.40 |
5,000 |
72,000 |
38,300 |
| Noci Darlene | Chief Development Officer |
Nov 01 '24 |
Sale |
88.60 |
5,000 |
442,980 |
33,300 |
| Balcom Alexandra | Chief Financial Officer |
Oct 31 '24 |
Option Exercise |
27.85 |
10,000 |
278,500 |
43,300 |
| Balcom Alexandra | Chief Financial Officer |
Oct 31 '24 |
Sale |
89.19 |
10,000 |
891,879 |
33,300 |
| Shair Matthew | Director |
Oct 28 '24 |
Sale |
91.73 |
2,000 |
183,468 |
224,522 |
| Flynn James E | Director |
Oct 22 '24 |
Sale |
97.75 |
2,000,000 |
195,500,000 |
8,670,512 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):